19.11.2026
Major Milestone in Tuberculosis Treatment
An international clinical research network has identified two drug combinations with the potential to substantially shorten the duration of tuberculosis treatment without compromising efficacy or tolerability. The findings have now been published in the internationally renowned New England Journal of Medicine.
Tuberculosis treatment is lengthy and is often associated with considerable adverse effects. Shorter treatment regimens could not only reduce the physical and psychological burden on patients, but also lower the risk of treatment discontinuation and the associated development of drug resistance.
To address this challenge, the international UNITE4TB research consortium, funded by the European Commission and involving the Borstel Research Center, Leibniz Lung Center (FZB), as a leading partner, is investigating ten drug combinations in parallel. These regimens combine established and novel antibiotics targeting tuberculosis bacteria.
Novel compounds with different mechanisms of action
The novel compounds under investigation include ganfeborole and BTZ-043. Ganfeborole inhibits the production of essential proteins in the bacteria. BTZ-043, by contrast, blocks an enzyme required for the synthesis of the bacterial cell wall. Both compounds therefore offer new opportunities for developing effective tuberculosis treatment regimens.
The aim of the Phase 2B study was to identify treatment regimens with the potential to achieve effective treatment within just 16 weeks, compared with the current 24-week standard, while demonstrating non-inferior efficacy. A total of 401 people with pulmonary tuberculosis participated in the study.
Two promising combinations for shorter treatment regimens
Two of the drug combinations investigated showed particularly promising results: ganfeborole in combination with bedaquiline, pretomanid and moxifloxacin, and BTZ-043 in combination with bedaquiline, delamanid and moxifloxacin.
Contact
Prof. Dr. med. Dr. h.c. Christoph Lange DZIF TTU TB (ClinTB)
T +49 4537 / 188-3010 (Sekretariat)
F +49 4537 / 188-6030
clange@fz-borstel.de
Both regimens substantially reduced the bacterial burden. In particular, the BTZ-043-containing regimen showed a high probability of achieving greater antibacterial activity than the current standard treatment. This probability was 83% for the ganfeborole-containing regimen and as high as 99% for the BTZ-043-containing regimen. These estimates were based on changes in bacterial burden during the first 12 weeks of treatment.
The two selected treatment regimens are now being investigated in the next stage of the study, Phase 2C, to determine the shortest treatment duration that achieves a durable cure without subsequent disease relapse.
A total of 70 of the planned 440 participants have already been enrolled. Brazil has now also joined the Phase 2C study, bringing a South American country into the international research programme.
"Developing shorter and better-tolerated tuberculosis treatment regimens is a major challenge for international research. This study demonstrates how innovative trial designs and international collaboration can help identify promising drug combinations more rapidly and advance new treatment options for patients," says Professor Christoph Lange, Medical Director of the Research Center Borstel, Leibniz Lung Center, and one of UNITE4TB's clinical leads, summarising the findings.
Publication: Esmail H, Paton NI, Schildkraut JA, et al. Assessing Multiple Treatment Regimens for Tuberculosis. New England Journal of Medicine. Published November 19, 2026. doi:10.1056/NEJMoa2611913.